As of 2026-03-23, the EV/EBITDA ratio of WAVE Life Sciences Ltd (WVE) is -7.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. WVE's latest enterprise value is 1,611.75 mil USD. WVE's TTM EBITDA according to its financial statements is -211.42 mil USD. Dividing these 2 quantities gives us the above WVE EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 1.5x - 2.5x | 2.0x |
| Forward P/E multiples | 1.2x - 1.4x | 1.3x |
| Fair Price | 1.56 - 1.60 | 1.35 |
| Upside | -86.7% - -86.4% | -88.6% |
| Date | EV/EBITDA |
| 2026-03-19 | -7.94 |
| 2026-03-18 | -7.75 |
| 2026-03-17 | -8.25 |
| 2026-03-16 | -8.20 |
| 2026-03-13 | -8.75 |
| 2026-03-12 | -9.04 |
| 2026-03-11 | -9.69 |
| 2026-03-10 | -9.40 |
| 2026-03-09 | -8.99 |
| 2026-03-06 | -8.83 |
| 2026-03-05 | -8.91 |
| 2026-03-04 | -9.36 |
| 2026-03-03 | -9.12 |
| 2026-03-02 | -9.48 |
| 2026-02-27 | -9.56 |
| 2026-02-26 | -10.83 |
| 2026-02-25 | -10.10 |
| 2026-02-24 | -9.64 |
| 2026-02-23 | -9.17 |
| 2026-02-20 | -9.16 |
| 2026-02-19 | -8.87 |
| 2026-02-18 | -8.81 |
| 2026-02-17 | -8.36 |
| 2026-02-13 | -8.44 |
| 2026-02-12 | -8.55 |
| 2026-02-11 | -8.97 |
| 2026-02-10 | -9.25 |
| 2026-02-09 | -9.32 |
| 2026-02-06 | -9.13 |
| 2026-02-05 | -8.51 |
| 2026-02-04 | -9.02 |
| 2026-02-03 | -9.35 |
| 2026-02-02 | -9.11 |
| 2026-01-30 | -8.67 |
| 2026-01-29 | -8.74 |
| 2026-01-28 | -8.49 |
| 2026-01-27 | -9.05 |
| 2026-01-26 | -8.95 |
| 2026-01-23 | -9.15 |
| 2026-01-22 | -9.46 |
| 2026-01-21 | -9.56 |
| 2026-01-20 | -9.46 |
| 2026-01-16 | -9.31 |
| 2026-01-15 | -9.68 |
| 2026-01-14 | -10.07 |
| 2026-01-13 | -9.81 |
| 2026-01-12 | -9.54 |
| 2026-01-09 | -9.48 |
| 2026-01-08 | -10.36 |
| 2026-01-07 | -10.89 |